# Supplementary material

## Supplementary table 1: Primary outcome according to quartile and modified quartile analysis

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Quartile analysis | HR | 95,0% CI pour Exp(B) | | Sig. |
| Lower | Higher |
| Furosemide Quartile 1: ≤40 mg | 1 |  |  |  |
| Furosemide Quartile 2: 40-100 mg | 1.44 | 0.87 | 2.38 | 0.16 |
| Furosemide Quartile 3: 100-250 | 1.12 | 0.67 | 1.88 | 0.66 |
| Furosemide Quartile 4: >250 mg | **1.76** | **1.06** | **2.93** | **0.03** |
| Modified quartile analysis | HR | 95,0% CI pour Exp(B) | | Sig. |
| Lower | Higher |
| Furosemide ≤40 mg | 1 |  |  |  |
| Furosemide 40-80 mg | 1.37 | 0.82 | 2.29 | 0.22 |
| Furosemide 81-250 mg | 1.18 | 0.71 | 1.96 | 0.51 |
| Furosemide >250 mg | **1.75** | **1.05** | **2.92** | **0.03** |

## Supplementary table 2: Adjusted association of furosemide dose groups with outcomes

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Adjusted model for age, gender, estimated glomerular filtration rate, BNP/NTproBNP Z-score, total bilirubin and PCWP as dichotomized variable (≤20 & > 20mmHg). | | | | |
|  | Furosemide equivalent dose  0-40 mg | Furosemide equivalent dose  41-250 mg | Furosemide equivalent dose  >250 mg | **Interaction p-value** |
| Waitlist mortality\* | Ref | 5,53 (0,70-43,85) p=0,11 | **14,54 (1,78- 118,40) p=0,01** | **0,457** |
| Waitlist mortality or urgent heart transplantation\*\* | Ref | 1,61 (0,78-3,34) p=0,20 | **2,99 (1,34-6,64) p=0,01** | **0,203** |
| Waitlist mortality, urgent heart transplantation or LVAD implantation\*\*\* | Ref | 1,50 (0,77-2,93) p=0,24 | **2,53 (1,19-5,38) p=0,02** | **0,163** |
| Waitlist mortality, delisting for aggravation, urgent heart transplantation or LVAD implantation\*\*\*\* | Ref | 1,15 (0,64-2,06) p=0,65 | **1,96 (1,00-3,83) p=0,05** | **0,605** |